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Abstract
Background: This longitudinal study aims to investigate differences in long-term disability between social anxiety
disorder (SAD), panic disorder with agoraphobia (PDA), panic disorder without agoraphobia (PD), generalized
anxiety disorder (GAD) and multiple anxiety disorders (multiple AD), focusing on the effects of different course
trajectories (remission, recurrence and chronic course) and specific symptom dimensions (anxiety arousal and
avoidance behaviour).
Methods: Data were used from participants with no psychiatric diagnosis (healthy controls, n = 647) or with a
current anxiety disorder (SAD, n = 191; PDA, n = 90; PD, n = 84; GAD, n = 110; multiple AD, n = 480). Severity of
anxiety arousal and avoidance behaviour symptoms was measured using the Beck Anxiety Inventory and the Fear
Questionnaire. The World Health Organization Disability Assessment Schedule II was used to measure disability.
Results: Long-term disability was most prevalent in participants with SAD and multiple AD, and lowest in PDA and
PD. GAD had an intermediate position. Anxiety arousal and avoidance behaviour were associated with more
long-term disability in anxiety disorders than course trajectories.
Conclusions: Various anxiety disorders have different disability levels over 4 years of time, therefore diagnostic
distinction is important for treatment focus. Anxiety arousal and avoidance behaviour are major predictors for
long-term disability in anxiety disorders.
Background
Disability is often defined as ‘any restriction or lack of
capacity to perform an activity in a manner or within a
range considered normal for a human being’ [1]. Anxiety
disorders are associated with severe disability [2–6] and
the negative impact of anxiety is substantial [3, 7, 8].
Previous research showed that anxiety disorders differ in
disability levels. Overall, multiple anxiety disorders (mul-
tiple AD, i.e. comorbidity with other anxiety disorders)
are associated with more disability than pure anxiety dis-
orders [9]. Furthermore, social anxiety disorder (SAD)
and generalized anxiety disorder (GAD) are associated
with higher disability levels compared to panic disorder,
[3, 10–12] although other research points out otherwise
[13–15]. However, it remains unclear whether contrasts
in disability levels among anxiety disorders persist over a
longer period.
More severe symptoms and more comorbidity are associ-
ated with a chronic course in anxiety disorders [16–20].
Therefore, we expect that long-term disability is more com-
mon in anxiety patients with a chronic course. However,
some research gave indications that disability can still be
present after remission of the anxiety disorder [21]. Because
SAD and multiple AD are more strongly associated with a
chronic course than other anxiety disorders [19, 22–24] we
expect that long-term disability therefore is more prevalent
in SAD and multiple AD.
Furthermore, previous research showed that symptom
dimensions, like anxiety arousal and avoidance behaviour,
can be strong predictors [19, 20, 25]. Hendriks et al. [19]
showed that avoidance behaviour symptoms may be more
important predictors than the symptoms of anxiety itself.
This would lead to the hypothesis that long-term disability
is more frequently seen in panic disorder with agorapho-
bia (PDA) and SAD compared to panic disorder without
agoraphobia (PD) and GAD because of the high levels of
avoidance behaviour in PDA and SAD.
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This longitudinal study among a large cohort of partici-
pants with anxiety disorders investigates: 1) differences in
long-term disability between participants with social anxiety
disorder (SAD), panic disorder with agoraphobia (PDA),
panic disorder without agoraphobia (PD), generalized anx-
iety disorder (GAD) and multiple anxiety disorders (mul-
tiple AD); 2) differences in long-term disability for different
course trajectories; and 3) the role of anxiety arousal and
avoidance behaviour in long-term disability.
Methods
Study sample
As reported before, [11, 19, 20]. The Netherlands Study
of Depression and Anxiety (NESDA) is a naturalistic co-
hort study to examine the long-term course and conse-
quences of anxiety and depressive disorders [26]. In short,
a total of 2981 participants were included, aged 18 through
65 years. The research protocol was approved centrally by
the ethical review board of VU University Medical Center.
Subsequently it was approved by the local ethical review
boards of Leiden University Medical Center and University
Medical Center Groningen. The study was performed in
accordance with the ethical standards of the Declaration of
Helsinki. All participants provided written informed con-
sent. Participants with a current or lifetime diagnosis of
anxiety or depression, and healthy controls were included.
Exclusion criteria were (1) a primary diagnosis of psych-
otic, obsessive compulsive, bipolar or severe addiction dis-
order, and (2) not being fluent in Dutch.
Participants with an anxiety disorder (SAD, PDA, PD,
GAD and multiple AD) at baseline (6-month recency
diagnosis) and healthy controls were included for this study
(Fig. 1). A follow-up assessment was done two (T1) and
4 years (T2) after the baseline measurement. In total 1602
participants met these criteria at T0 (baseline); 191 partici-
pants (11.9 %) with pure SAD, 90 participants (5.6 %) with
pure PDA, 84 participants (5.2 %) with pure PD, 110 par-
ticipants (6.9 %) with pure GAD, 480 participants (30.0 %)
with multiple AD and 647 healthy controls (40.4 %). 1351
participants (84.3 %) had a follow-up assessment at T1,
and 1235 participants (77.1 %) at T2.
Psychiatric status
As done before, [11, 19, 20] the Composite International
Diagnostic Interview (CIDI version 2.1) was used to
diagnose the presence of SAD, PDA, PD, GAD and mul-
tiple AD, a highly reliable and valid instrument for asses-
sing anxiety disorders [27].
Course trajectory
The clinical course trajectory categorized the participants
into four groups: a) healthy controls (no history of anxiety
disorder and no anxiety disorder at T0, T1 and T2), b) re-
mission (remission of baseline anxiety disorder at T1 and/
or T2 without recurrence), c) recurrence (remission of
baseline anxiety disorder at T1 but with recurrence at T2),
and d) chronic course (baseline anxiety disorder at T0, T1
and T2).
Anxiety arousal and avoidance behaviour
As done before, [11, 19, 20] the Beck Anxiety Inventory
(BAI) [28] and the Fear Questionnaire (Fear Q) [29]
Fig. 1 Flowchart of study sample
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were used to measure baseline severity of anxiety arousal
and avoidance behaviour symptoms, respectively. The BAI
and the Fear Q are both widely used and have proven to
be highly valid and reliable [30, 31]. The Cronbach’s α in
this study for the BAI and the Fear Q were .94 and .89,
respectively.
Disability
To measure disability at baseline, after two and after
4 years, we used the total score of the World Health
Organization Disability Assessment Schedule II.(WHO-
DAS-II) [32]. The WHODAS-II provides a functioning
profile for six activity domains (cognition, mobility, self-
care, social interaction, life activities and participation).
To measure general disability, domain scores were com-
bined into a total score. The WHODAS-II shows good
inter-item reliability with a Cronbach’s α of .96 for the total
score. In Hendriks et al. [11] a cross sectional study was
conducted to compare the different disability domains of
the WHODAS-II between different anxiety disorders and
healthy controls. The results showed that disability was
generally highest in multiple anxiety disorder (e.g. mean
disability in cognition = 33.7) and social anxiety dis-
order (mean = 32.7), followed by generalized anxiety
disorder (mean = 27.2) and panic disorder with agorapho-
bia (mean = 26.3), and lowest in panic disorder without
agoraphobia (mean = 22.1). This pattern was consistently
present across different disability domains, therefore for
this study we choose to use only the total score of the
WHODAS-II.
Covariates
As done before, [11] covariates at baseline were set: age,
gender, years of education attained, partner status, num-
ber of somatic illnesses and comorbid depressive dis-
order. Previous studies showed that these covariates are
associated with both anxiety and disability [33, 34].
Statistical analyses
SPSS Version 20.0 (SPSS Inc, Chicago, Illinois) was used
for the statistical analyses. We used chi-square statistics for
categorical and analyses of variance for continuous vari-
ables to compare sociodemographic, clinical psychiatric
characteristics and long-term disability between healthy
controls and participants with anxiety disorders. Linear
mixed models (LMM) [35] were used to analyse the rela-
tionship between 1) baseline psychiatric status, 2) course
trajectories and 3) symptom dimensions with the outcome
long-term disability.
Results
Table 1 presents the demographic and clinical characteris-
tics of the total sample. A chronic course was most preva-
lent in the multiple AD group (35.1 %). After 4 years
64.9 % of the participants with SAD, 68.6 % of PDA, 65.6 %
of PD, 79.7 % of GAD and 51.1 % of multiple AD were
without an anxiety disorder (X2 = 355.5, df = 25, p < .001).
Anxiety arousal and avoidance behaviour symptoms were
highest in the multiple AD group compared to other
groups (BAI F = 286.2, df = 5, p < .001; Fear Q F = 205.12,
df = 5, p < .001).
Figure 2 shows 4-year disability patterns between partici-
pants with SAD, PDA, PD, GAD, multiple AD and healthy
controls (n = 1235) at each time point. Healthy controls ex-
perienced less disability compared to participants with any
anxiety disorder and this differed significantly at baseline
(all p-values < .001), 2-year follow-up (all p-values < .05) and
4-year follow-up (all p-values < .04). Generally, SAD and
multiple AD participants experienced most disability. Dis-
ability was lowest in PDA and PD, and GAD had an inter-
mediate position. At baseline, participants with SAD, GAD
and multiple AD experienced more disability than partici-
pants with PDA and PD (all p-values < .03). Participants
with multiple AD had more disability than participants with
PD at 2 years (T1) (p = .01). At 4 years (T2), participants
with SAD showed more disability than participants with
PDA (p = .02), and participants with multiple AD showed
more disability than participants with PD (p = .01) and
PDA (p = .02).
Table 2 shows LMM analyses for long-term disability.
Univariable analyses indicate that having an anxiety dis-
order at baseline predicts long-term disability. SAD x time,
PDA x time, GAD x time and multiple AD x time showed
significant negative associations. This indicates that during
follow-up the impact of the disorders on long-term disabil-
ity became smaller. Course trajectories (remission, re-
currence and chronic course) and symptom dimensions
(anxiety arousal and avoidance behaviour) were also as-
sociated with long-term disability. No associations were
found for symptom dimensions x time, suggesting that
associations did not significantly change over time.
In Model 1 the degree was examined to which course
trajectories contribute to long-term disability across anxiety
disorders. Baseline psychiatric status and chronic course
remained significant predictors. Also SAD x time, PDA x
time, GAD x time and multiple AD x time remained sig-
nificant. This indicates that during follow-up the impact of
baseline SAD, PDA, GAD and multiple AD on long-term
disability became smaller.
In Model 2 baseline psychiatric status and symptom
dimensions were assessed together. The results show that
all coefficients decreased notably and only SAD, GAD,
multiple AD, anxiety arousal and avoidance behaviour
remained significant. PDA and PD did not remain sig-
nificant. This indicates that anxiety arousal and avoid-
ance behaviour lead to more long-term disability in
anxiety disorders, which especially explain the found
disability levels in PD and PDA.
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Fig. 2 Disability (total score WHODAS-II) over 4 years of time for baseline psychiatric status (n = 1235) *
Table 1 Demographic and clinical characteristics of the total sample (healthy controls and participants with different anxiety disorders,
n = 1602)
Healthy controls SAD PDA PD GAD Multiple AD pa
n = 647 n = 191 n = 90 n = 84 n = 110 n = 480
Sociodemographics
Age (mean, SD) 41.1 (14.6) 37.3 (11.9) 40.1 (12.5) 38.3 (11.1) 37.4 (12.0) 40.8 (11.7) .001
Sex (% female) 61.7 64.9 74.4 59.5 69.1 68.5 .05
Education (mean, SD) 12.8 (3.2) 12.6 (3.2) 12.1 (3.4) 12.4 (3.1) 12.4 (3.1) 11.3 (3.3) <.001
Partner status (% yes) 75.0 56.5 70.0 73.8 70.0 63.8 <.001
Clinical psychiatric characteristics
Number of somatic illnesses (mean, SD) 0.7 (1.0) 0.8 (0.9) 0.9 (1.0) 0.7 (0.8) 0.7 (0.9) 1.1 (1.2) <.001
Comorbid depressive disorder (%) 0 41.9 38.7 40.5 62.7 72.5 <.001
Psychiatric course trajectories (%) <.001
Remission - 72.3 87.1 81.2 91.1 51.1
Recurrence - 10.8 4.3 14.1 7.6 13.8
Chronic course - 16.9 8.6 4.7 1.3 35.1
Psychiatric status after 4 years (%) <.001
No anxiety disorder - 64.9 68.6 65.6 79.7 51.1
Social anxiety disorder - 20.9 2.9 3.1 7.6 16.8
Panic disorder with agoraphobia - 0 8.6 4.7 0 6.3
Panic disorder without agoraphobia - 2.0 8.6 12.5 3.8 6.3
Generalized anxiety disorder - 4.1 5.7 1.6 8.9 7.2
Multiple anxiety disorder - 8.1 5.7 12.5 0 12.3
Symptom dimensions
Anxiety arousal (BAI, mean, SD) 4.1 (4.9) 13.9 (9.1) 19.1 (11.6) 14.2 (8.9) 14.6 (8.2) 23.1 (11.1) <.001
Avoidance behaviour (Fear Q, mean, SD) 12.1 (12.2) 34.4 (18.8) 32.1 (19.0) 22.8 (18.1) 25.0 (16.3) 43.7 (20.6) <.001
ap-value based on chi-square statistics for categorical variables and analyses of variances for continuous variables
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In Model 3, baseline psychiatric status, course trajector-
ies and symptom dimensions were assessed together.
SAD, GAD, multiple AD, anxiety arousal and avoidance
behaviour remained significant but course trajectories not.
Furthermore, SAD x time and GAD x time remained sig-
nificant. This indicates that the impact of SAD and GAD
on long-term disability remained irrespective of course
and symptom dimensions.
Discussion
The results showed that all anxiety disorders were associ-
ated with more disability over 4 years of time compared to
healthy controls, though differences became smaller over
time.
Long-term disability was most prevalent in participants
with SAD and multiple AD, and lowest in PDA and PD.
GAD had an intermediate position. Furthermore, we found
differences between course trajectories; a chronic course
predicts long-term disability better than remission and re-
currence. However, symptom dimensions seem to be
stronger predictors of long-term disability than course
trajectories.
Our finding that long-term disability is more prevalent in
SAD and multiple AD compared to other anxiety disor-
ders, is in line with previous results [36, 37] Because SAD
and multiple AD are more associated with a chronic course
than other anxiety disorders [20, 22, 23] and a chronic
course is associated with more disability, [21] we expected
that long-term disability is more prevalent in SAD and
multiple AD. Our results showed that a chronic course is
indeed associated with long-term disability. Avoidance be-
haviour was also associated with long-term disability in our
study. We hypothesised that long-term disability would be
high in SAD, PDA and multiple AD because of the high
levels of avoidance behaviour in these disorder. However,
PDA had a low position. So the assumption that avoidance
behaviour predicts long-term disability better than anxiety
arousal seems to be debatable.
Our findings showed intermediate associations for
long-term disability and GAD. The association between
GAD and disability may be particularly strong because
Table 2 Linear mixed model analyses for long-term disability (total score WHODAS-II)a
Disability
Univariable Model 1 Model 2 Model 3
ß (SE) p ß (SE) p ß (SE) p ß (SE) p
Baseline psychiatric status
Healthy controls Ref Ref Ref Ref
SAD 15.28 (1.55) <.001 14.26 (1.74) <.001 5.09 (1.42) <.001 4.38 (1.55) <.001
SAD x time -6.48 (0.61) <.001 -6.40 (0.61) <.001 -2.52 (0.57) .01 -2.56 (0.57) .01
PDA 9.31 (2.09) <.001 9.54 (2.24) <.001 -0.46 (1.88) .65 -0.65 (1.98) .52
PDA x time -4.18 (0.85) <.001 -4.04 (0.85) <.001 -0.07 (0.77) .94 -0.11 (0.77) .92
PD 5.96 (2.15) <.001 6.40 (2.29) <.001 0.46 (1.84) .65 0.23 (1.94) .82
PD x time -1.43 (0.88) .15 -1.29 (0.88) .20 -0.07 (0.77) .95 -0.11 (0.77) .92
GAD 13.01 (1.93) <.001 13.19 (2.07) <.001 6.62 (1.68) <.001 6.07 (1.77) <.001
GAD x time -5.80 (0.79) <.001 -5.58 (0.80) <.001 -3.52 (0.70) <.001 -3.55 (0.70) <.001
Multiple AD 20.93 (1.57) <.001 18.21 (1.58) <.001 3.58 (1.46) <.001 3.00 (1.58) .003
Multiple AD x time -7.61 (0.54) <.001 -7.54 (0.54) <.001 -1.31 (0.58) .19 -1.36 (0.58) .18
Psychiatric course trajectory
Healthy controls Ref Ref Ref
Remission 10.30 (0.82) <.001 -3.12 (1.12) .002 0.63 (0.84) .53
Recurrence 7.82 (1.66) <.001 -0.01 (1.70) .99 0.42 (1.23) .67
Chronic course 14.65 (1.32) <.001 3.65 (1.48) <.001 0.94 (1.08) .35
Symptom dimensions
Anxiety arousal 24.28 (0.04) <.001 12.49 (0.06) <.001 12.51 (0.06) <.001
Anxiety arousal x time 1.49 (0.02) .14 0.90 (0.03) .37 0.86 (0.03) .39
Avoidance behaviour 23.28 (0.02) <.001 10.58 (0.03) <.001 10.57 (0.03) <.001
Avoidance behaviour x time -1.40 (0.01) .16 0.17 (0.01) .87 0.14 (0.01) .89
aAnalyses corrected for covariates age, sex, education, partner status, number of somatic illnesses and comorbid depression
Model 1: baseline psychiatric status and course trajectories; Model 2: baseline psychiatric status and symptom dimensions; Model 3: final model
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worry is pervasive and can be focused on any area (more
general concerns, including social situations and physical
concerns), whereas the focus of distress for SAD, PDA
and PD is more narrow. Nevertheless, this finding is
only partly in line with previous results. Naragon-Gainey
et al. [12] found that GAD at baseline was more associ-
ated with severe disability in certain areas (i.e. work,
household, family, private leisure) compared to SAD and
PDA/PD. However, after 2 years participants with GAD
at baseline experienced no more disability than partici-
pants with SAD and PDA/PD. Previous research showed
that comorbidity between GAD and other mental disor-
ders is high (e.g. major depressive disorder) [5, 38–41].
Possibly, this high comorbidity can explain the inconsist-
ent results among previous research. However, other re-
search pointed out that the disability seen in GAD
cannot be explained by comorbidity [42].
The results showed that long-term disability is lowest
in PDA and PD which is partly in line with other studies
[12, 13]. As mentioned in our previous study [11], dis-
ability in PDA and PD is generally associated with phys-
ical disability [14, 37]. Unfortunately, physical disability
is not measured by the WHODAS-II very well and we
can therefore not establish whether PDA and PD partici-
pants in this study have more physical disability com-
pared to other participants.
Baseline psychiatric status and symptom dimensions
were stronger predictors for long-term disability than
course trajectories. This indicates that participants with
SAD, GAD and multiple AD remain more disabled than
PDA and PD, despite the course. Furthermore, although
remission rates were relatively high, participants with
anxiety disorders at baseline remain more disabled than
healthy controls after 4 years. Possibly, baseline psychi-
atric status contains important information which was
not measured in our study, such as age of onset, envir-
onmental factors, personality characteristics, and pre-
morbid functioning. Another possibility is that when
participants remit over 4 years, subthreshold anxiety
symptoms may still be present and cause disability. Pre-
vious research indeed showed that subthreshold anxiety
is also associated with long-term disability [43, 44].
This study has several strengths. Adequate analyses were
performed because of the structured psychiatric interview,
the large representative sample, and the longitudinal de-
sign. LMM analyses made it possible that all available in-
formation was used, even from participants with partly
missing data. This study has also limitations. First, not all
anxiety disorders are included in NESDA (e.g., obsessive
compulsive disorder, posttraumatic stress disorder and spe-
cific phobia). However, in this study DSM-IV diagnoses
were used instead of DSM-5. In DSM-5 obsessive compul-
sive disorder and posttraumatic stress disorder do not be-
long to the anxiety disorders chapter anymore and are
discussed in separate chapters. Next, participants with de-
pressive disorders were not excluded but analyses were
corrected for comorbid depression. Furthermore, there can
be differences in disability in the duration of a chronic dis-
order. For example, having a chronic anxiety disorder for
20 years causes possibly a different level of disability than
having a chronic anxiety disorder for 5 years.
Conclusions
Generally, long-term disability was highest in participants
with SAD and multiple AD, followed by participants with
GAD, and lowest in participants with PDA and PD. This
means that various anxiety disorders have different disabil-
ity levels over 4 years of time, so diagnostic distinction is
important for treatment focus. When there is more than
one anxiety disorder present there must be examined which
anxiety symptoms are the most severe and disabling for the
patient so treatment can focus on these symptoms. Our re-
sults show that anxiety arousal and avoidance behaviour
lead to more long-term disability in anxiety disorders com-
pared to course trajectories. Taken together, symptom di-
mensions in anxiety disorders give important information
about disability over time. The use of symptom dimensions
could eventually give more insight in all the complex asso-
ciations in psychopathology and determine how psychiatric
problems develop over time. The efficacy of transdiagnostic
interventions for anxiety disorder patients (e.g. acceptance
and commitment therapy and cognitive behavioural ther-
apy) which are targeting these underlying processes might
be evaluated or new interventions can be developed in
order to prevent long-term disability. The results of our
studies support the concepts of the DSM-5, which includes
dimensional aspects of diagnosis along with categories.
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